Relmada Therapeutics (RLMD) Total Current Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Total Current Liabilities data on file, last reported at $12.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $12.9 million, up 146.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.9 million (up 146.43% YoY), and the FY2025 annual result was $6.4 million, down 37.52% from the prior year.
• Total Current Liabilities climbed to $12.9 million in Q1 2026 per RLMD's latest filing, from $6.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $20.8 million in Q3 2022 and troughed at $5.1 million in Q2 2025.
• A 5-year average of $10.8 million and a median of $10.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities plunged 59.46% in 2023, then soared 146.43% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $12.5 million in 2022, then fell by 2.2% to $12.2 million in 2023, then declined by 15.61% to $10.3 million in 2024, then tumbled by 37.52% to $6.4 million in 2025, then soared by 100.48% to $12.9 million in 2026.
• Business Quant data shows RLMD's Total Current Liabilities at $12.9 million in Q1 2026, $6.4 million in Q4 2025, and $5.2 million in Q3 2025.